Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.58 |
| ▸ | CASP1 | P29466 | 5/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910765 | 1.00 | FOLH1 (0.58) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL2921260 | 0.93 | FOLH1 (0.59) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL7624700 | 0.93 | FOLH1 (0.59) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL677997 | 0.93 | FOLH1 (0.59) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL11059124 | 0.90 | MME (0.52) | FOLH1CASP1MMEECE1CTSK | |
| SCHEMBL221391 | 0.90 | KYNU (0.60) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL6259518 | 0.90 | KYNU (0.60) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL2777678 | 0.90 | KYNU (0.60) | FOLH1CASP1MMEECE1HTT | |
| SCHEMBL910423 | 0.90 | FOLH1 (0.70) | FOLH1CASP1MMEECE1 | |
| SCHEMBL910233 | 0.90 | FOLH1 (0.70) | FOLH1CASP1MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331030-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) | 2025-06-17 | — | — | US | disclosed |
| US-20240132466-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING | TIANJIN HEMAY PHARMACEUTICAL SCI TECH CO LTD (CN) | 2024-04-25 | — | — | US | disclosed |
| US-11873287-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20220372013-A2 | PIPERIDINE-2,6-DIONE DERIVATIVES AND CROHN'S DISEASE TREATING | GANZHOU HEMAY PHARMACEUTICAL, CO., LTD (CN) | 2022-11-24 | — | — | US | disclosed |
| US-11485724-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) | 2022-11-01 | — | — | US | disclosed |
| US-20220306600-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING | TIANJIN HEMAY PHARMACEUTICAL SCI TECH CO LTD (CN) | 2022-09-29 | — | — | US | disclosed |
| US-20190352277-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES AND CROHN'S DISEASE TREATING | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3546449-A1 | PIPERIDINE-2,6-DIKETONE DERIVATIVE AND TREATMENT FOR CROHN'S DISEASE | Tianjin Hemay Bio-Tech Co., Ltd (CN) | 2019-10-02 | — | — | EP | disclosed |
| EP-3546450-A1 | PIPERIDINE-2,6-DIONE DERIVATIVE AND TREATMENT FOR ULCERATIVE COLITIS | Tianjin Hemay Bio-Tech Co., Ltd (CN) | 2019-10-02 | — | — | EP | disclosed |
| US-4864023-A | MICROBIOCIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4801584-A | ANTIMICROBIAL | HOFFMANN-LA ROCHE INC. (US) | 1989-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132466-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING | DPYD, PTGDR2, UCK2 | FOLH1 834/4885CASP1 1378/4885MME 4399/4885 |
| US-20190352277-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES AND CROHN'S DISEASE TREATING | PTGDR2, PTGDR, TPMT | FOLH1 472/4885CASP1 1590/4885MME 3908/4885 |
| US-12331030-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | DPYD, PTGDR2, UCK2 | FOLH1 834/4885CASP1 1378/4885MME 4399/4885 |
| US-11485724-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | DPYD, PTGDR2, UCK2 | FOLH1 834/4885CASP1 1378/4885MME 4399/4885 |
| US-11873287-B2 | Piperidine-2,6-dione derivatives and ulcerative colitis treating | DPYD, PTGDR2, UCK2 | FOLH1 834/4885CASP1 1378/4885MME 4399/4885 |
| US-20220372013-A2 | PIPERIDINE-2,6-DIONE DERIVATIVES AND CROHN'S DISEASE TREATING | PTGDR2, PTGDR, TPMT | FOLH1 472/4885CASP1 1590/4885MME 3908/4885 |
| US-20220306600-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING | DPYD, PTGDR2, UCK2 | FOLH1 834/4885CASP1 1378/4885MME 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.